Veklury approved for COVID-19 with hepatic impairment

The US Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the use of Veklury (remdesivir) with no dose adjustments to treat COVID-19 in people with mild, moderate and severe hepatic impairment.

This comes nearly three years after Gilead Sciences’ (Nasdaq: GILD) antiviral medicine became the first drug to get full FDA approval for COVID-19 during the worst of the global pandemic.

"This approval demonstrates Gilead’s ongoing commitment to COVID-19, including our focus on vulnerable populations"While COVID-19 is no longer regarded as a public health emergency, the virus continues to present a threat to those with underlying conditions.